Clinical Study
Immunohistochemical Evaluation of Cell Cycle Regulators: Impact on Predicting Prognosis in Stage T1 Urinary Bladder Cancer
Table 2
Characteristics of the 201 patients included in the study.
| | | Recurrence T1
| Progression
| | | No
40 (20%) | Yes
161 (80%) | No
124 (62%) | Yes
77 (38%) |
| | Gender | | | | | | Male | 34 (21%) | 132 (79%) | 102 (62%) | 64 (38%) | | Female | 6 (17%) | 29 (83%) | 22 (61%) | 13 (39%) | | WHO 99 | | | | | | Grade 1 | 0 | 0 | 0 | 0 | | Grade 2 | 4 (12%) | 26 (78%) | 20 (67%) | 10 (33%) | | Grade 3 | 36 (21%) | 135 (79%) | 104 (61%) | 67 (39%) | | Tumour size | | | | | | ≤30 mm | 24 (26%) | 71 (74%) | 60 (63%) | 35 (37%) | | >30 mm | 16 (15%) | 90 (85%) | 64 (60%) | 42 (40%) | | Multiplicity | | | | | | Yes | 32 (23%) | 110 (67%) | 86 (61%) | 56 (39%) | | No | 7 (12%) | 51 (88%) | 38 (64%) | 21 (36%) | | p53 | | | | | | Normal | 4 (8%) | 45 (92%) | 26 (53%) | 23 (47%) | | Abnormal | 36 (24%) | 116 (76%) | 98 (64%) | 54 (36%) | | p16 | | | | | | Normal | 24 (23%) | 79 (77%) | 70 (68%) | 33 (72%) | | Abnormal | 16 (16%) | 82 (84%) | 54 (55%) | 44 (45%) | | pRb | | | | | | Normal | 6 (18%) | 27 (82%) | 14 (42%) | 19 (58%) | | Abnormal | 34 (20%) | 134 (80%) | 110 (65%) | 58 (35%) | | Cyclin D1 | | | | | | Normal | 15 (24%) | 47 (76%) | 32 (53%) | 30 (47%) | | Abnormal | 29 (20%) | 114 (80%) | 96 (67%) | 47 (33%) | | p21 | | | | | | Normal | 7 (12%) | 42 (88%) | 32 (54%) | 17 (46%) | | Abnormal | 32 (21%) | 119 (79%) | 92 (61%) | 59 (39%) | | MMP2 | | | | | | Normal | 38 (21%) | 147 (79%) | 114 (63%) | 71 (37%) | | Abnormal | 4 (22%) | 14 (78%) | 12 (67%) | 6 (33%) | | MMP9 | | | | | | Normal | 35 (21%) | 128 (79%) | 104 (64%) | 59 (36%) | | Abnormal | 5 (13%) | 33 (87%) | 20 (53%) | 18 (47%) |
|
|
